Chimerix (NASDAQ: CMRX)
Chimerix Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Chimerix Company Info
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
News & Analysis
3 Monkeypox Stocks That Soared Last Week
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
Here's Why Chimerix Stock Is Imploding Today
Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.
Why Chimerix Stock Skyrocketed on Friday
A new acquisition could be quite the shot in the arm for the company.
Could These 2 Biotech Stocks Really Double Your Money?
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
Here's Why Chimerix Inc Jumped 14.3% in April
This once-promising clinical-stage company is trying to prove that it's not dead yet, but investors remain skeptical.
Chimerix Inc. Is Roaring Higher Again -- Here's Why
Analysts and investors continue to warm up to the company's shares after their December implosion.
Why Chimerix Inc. Is Up Big Today
Shares are recovering today from their massive sell-off, but the company's near-term future remains a mystery.
Why Tetraphase Pharmaceuticals Plunged 74% in 2015
Sometimes bad things happen.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.